AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Elisabetta TodiscoCristina PapayannidisNicola FracchiollaElisabetta PetracciChiara ZingarettiCalogero VetroMaria Paola MartelliPatrizia ZappasodiNicola Di RenzoSusanna GalloErnesta AudisioDavide GriguoloClaudio CerchioneCarmine SelleriDaniele MatteiMassimo BernardiMonica FumagalliGiuliana RizzutoLuca FacchiniClaudia Maria BasilicoIlenia ManfraErika BorlenghiRoberto CairoliPrassede SalutariMichele GottardiAlfredo MolteniVincenza MartiniMonia LunghiLuana FianchiDaniela CilloniFrancesco LanzaElisabetta AbruzzeseNicola CascavillaFlavia RivelliniFelicetto FerraraLuca MaurilloJacopo NanniAlessandra RomanoValeria CardinaliFederica GigliElisa RoncoroniVincenzo FedericoGiovanni MarconiRoberta VolpiMariarita SciumèCorrado TarellaGiuseppe RossiGiovanni Martinellinull nullPublished in: Cancer (2023)
Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax + HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax + HMA effectiveness and toxicities in real life.
Keyphrases
- newly diagnosed
- acute myeloid leukemia
- chronic lymphocytic leukemia
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- electronic health record
- diffuse large b cell lymphoma
- multiple myeloma
- randomized controlled trial
- systematic review
- ejection fraction
- machine learning
- middle aged
- systemic lupus erythematosus
- deep learning